Chitravanshi VC, Sapru HN. Microinjections of urocortin1 into the nucleus ambiguus of the rat elicit bradycardia. Am J Physiol Heart Circ Physiol 300: H223-H229, 2011. First published October 15, 2010 doi:10.1152/ajpheart.00391.2010.-Urocortins are members of the hypothalamic corticotropin-releasing factor (CRF) peptide family. Urocortin1 (UCN1) mRNA has been reported to be expressed in the brainstem neurons. The present investigation was carried out to test the hypothesis that microinjections of UCN1 into the nucleus ambiguus (nAmb) may elicit cardiac effects. Urethane-anesthetized, artificially ventilated, adult male Wistar rats, weighing between 300 -350 g, were used. nAmb was identified by microinjections of Lglutamate (5 mM, 30 nl). Microinjections (30 nl) of different concentrations (0.062, 0.125, 0.25, and 0.5 mM) of UCN1 into the nAmb elicited bradycardic responses (26.5 Ϯ 1, 30.1 Ϯ 1.7, 46.9 Ϯ 1.7, and 40.3 Ϯ 2.6 beats/min, respectively). These heart rate responses were not accompanied by significant changes in mean arterial pressure. The bradycardic responses to maximally effective concentration of UCN1 (0.25 mM) were significantly (P Ͻ 0.05) attenuated by prior microinjections of a selective antagonist (NBI 27914, 1.5 mM) for CRF type 1 receptor (CRF1R). Prior microinjections of ionotropic glutamate receptor (iGLUR) antagonists [D-(Ϫ)-2-amino-7-phosphonoheptanoic acid and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo-(f)quinoxaline-7-sulfonamide disodium] also attenuated the bradycardia elicited by UCN1 microinjections into the nAmb. Microinjections of NBI 27914 (1.5 mM) into the nAmb did not alter baroreflex responses. Bilateral vagotomy abolished the bradycardic responses to microinjections of UCN1 into the nAmb. These results indicated that 1) microinjections of UCN1 into the nAmb elicited bradycardia, 2) the bradycardia was vagally mediated, 3) activation of CRF1Rs in the nAmb was responsible for the actions of UCN1, and 4) activation of iGLURs in the nAmb also participated in the bradycardia elicited by UCN1.
corticotropin-releasing factor receptors; vagus UROCORTINS ARE MEMBERS of the hypothalamic corticotropinreleasing factor (CRF) peptide family. These peptides include urocortin1 (UCN1, formerly known as urocortin), urocortin2 (UCN2, also known as stresscopin-related peptide), and urocortin3 (UCN3, also known as stresscopin) (11, 15, 18, 32) . Urocortins mediate their actions via CRF receptors (CRFRs). There are two major subtypes of CRF receptors, CRF1Rs and CRF2Rs (8, 12, 14) . These receptors are seven-transmembrane-domain G s protein-coupled receptors and stimulate adenylate cyclase activity.
Information regarding the neurocircuitry of UCN1 has been reviewed recently (17, 21, 34) and can be summarized as follows. Initial reports indicated that UCN1-containing cells were primarily located in the Edinger-Westphal nucleus (EWN), which is involved in ocular function. Subsequently it was demonstrated that UCN1-containing neurons were not identical with cholinergic neurons of the EWN and formed a separate group of cells that has been named as nonpreganglionic EWN (33) . In the hypothalamus, UCN1 is present in the supraoptic nucleus and lateral hypothalamus (23) . UCN1-containing cells have also been identified in other areas of the brainstem including the lateral superior olive and the facial and hypoglossal nuclei (4, 40) . UCN1-positive axons and terminals have been reported to be distributed diffusely throughout many brain regions and along the length of the spinal cord including lamina VII, which contains the sympathetic preganglionic neurons of the intermediolateral cell column (39) .
Peripheral administration of urocortins elicits decrease in systemic blood pressure (BP) and reduction of plasma concentrations of vasoconstrictor hormones such as angiotensin II, arginine vasopressin, and endothelin-1 (10, 40, 44) . Application of UCN2 to isolated adult rabbit ventricular cardiomyocytes exerts direct positive inotropic as well as lusitropic effects via activation of CRF2Rs (46) . In healthy humans, UCN2 infusion has been reported to increase cardiac output and decrease mean and diastolic BP and systemic vascular resistance (9) . There is increasing evidence that urocortins can be useful in the management of cardiovascular diseases such as heart failure, ischemic heart disease, and hypertension (41) . For example, in sheep with pacing-induced heart failure, administration of UCN1, UCN2, and UCN3 increased cardiac output and decreased peripheral resistance and left atrial pressure (29, 30, 31) . In the periphery, the positive inotropic and vasodilator effects of urocortins are mediated via activation of cardiac and vascular CRF2Rs, respectively.
CRFRs are distributed widely in the brain (8, 38) . The information available regarding the cardiovascular effects of activation of central CRFRs is limited. Because urocortins can reach the central nervous system via a unique transport mechanism (28), these peptides are expected to affect cardiovascular function. Indeed direct microinjections of urocortins into different brain regions elicit different responses. For example, microinjections of urocortins into the medial subnucleus of the nucleus tractus solitarius (mNTS) decrease BP and heart rate (HR) and sympathetic nerve activity (24, 25, 45) , whereas similar microinjections into the hypothalamic paraventricular nucleus elicit opposite responses (20) . The presence of UCN1 and CRF1Rs, but not UCN2, UCN3, or CRF2Rs, has been reported in the nucleus ambiguus (nAmb) of the rat (4, 18, 19, 32, 38, 40) . UCN1-immunoreactive fibers have also been identified in the ventral medulla, but the sources of these projections remain to be determined (4) . On the basis of these reports, it was hypothesized that activation of CRF1Rs in the nAmb by UCN1 may elicit cardiac effects. This hypothesis was tested in the present study by direct microinjections of UCN1 into the nAmb and area surrounding its compact portion, which is the predominant brain area providing parasympathetic innervation of the heart in the rat (2, 6, 26 -27, 37) .
MATERIALS AND METHODS
General procedures. Experiments were carried out in adult male Wistar rats (n ϭ 50) (Charles River Laboratories, Wilmington, MA) weighing 300 -350 g. All animals were housed under controlled conditions with a 12-h:12-h light/dark cycle. Food and water were available to the animals ad libitum. The experiments were performed according to the NIH Guide for the Care and Use of Laboratory Animals (7th Edition, 1996) and with the approval of the Institutional Animal Care and Use Committee of University of Medicine and Dentistry of New Jersey.
The general procedures have been described in detail elsewhere (7) . Briefly, the rats were anesthetized with inhalation of isoflurane (2-3% in 100% oxygen), the trachea was cannulated, and the rats were artificially ventilated to avoid cardiovascular effects secondary to respiratory changes, if any, induced by microinjections of UCN1 into the nAmb. The tidal volume and frequency on the ventilator were adjusted to maintain the end-tidal CO 2 at 3.5-4.5%. The end-tidal CO2 was measured continuously in the expired gas using an infrared CO2 analyzer for small animals. One of the femoral veins was cannulated, and urethane (1.2-1.4 g/kg) was injected intravenously in 12-15 aliquots at 2-min intervals. Isoflurane inhalation was terminated after the administration of five to six aliquots of urethane. Absence of withdrawal of the limb in response to pinching of a hind paw indicated that the rats were properly anesthetized. Rectal temperature was maintained at 36.5 Ϯ 0.5°C. One of the femoral arteries was cannulated, and BP was recorded using a polygraph. The BP signals were digitized, and mean arterial pressure (MAP) and HR signals were derived from them using 1401 A/D converter and Spike 2 software (Cambridge Electronic Design, Cambridge, UK). All of the tracings were stored on a computer hard drive.
Vagotomy. Vagotomy was necessary in experiments designed to investigate the role of parasympathetic innervation to the heart in mediating the UCN1-induced HR responses. In these experiments, silk sutures were placed loosely around the vagus nerves bilaterally for subsequent identification and sectioning.
Baroreflex function test. To measure the parasympathetic component of baroreflex, phenylephrine (PE) was infused intravenously and baroreflex function curves were obtained by plotting reflex decreases in HR in response to increases in MAP. The following protocol was used (7) . Approximately linear increase in MAP was induced by infusing PE (125 g/ml) with a 5-ml syringe connected to the femoral venous cannula and mounted on an infusion pump (model no. 341; Sage Instruments, Cambridge, MA). PE was administered continuously every 30 s by ramped infusion at a rate of 0.12, 0.17, and 0.25 ml/min until the MAP increased by 70 mmHg. The protocol was repeated after bilateral microinjections of artificial cerebrospinal fluid (aCSF) and CRF1R antagonist (NBI 27914; 1.5 mM) into the nAmb. In each experiment, PE infusions were made before any microinjections into the nAmb (control), after microinjection of aCSF, and after microinjection of CRF1R antagonist; the interval between PE infusions was at least 20 min.
Microinjections. The details of this technique have been described elsewhere (7) . Briefly, the rats were placed in a prone position in a stereotaxic instrument with bite bar 18 mm below the interaural line. The microinjections were made using a dorsal approach. Four-barreled glass micropipettes (tip size 20 -40 m) were mounted on a micromanipulator, and each barrel was connected to one of the channels on a picospritzer. One of the barrels contained L-glutamate (L-GLU), whereas the contents of other barrels varied according to the requirements of the experiment. The following coordinates were used for the identification of the nAmb: 0.3 caudal to 1.1 mm rostral and 1.8 -2.0 mm lateral to the calamus scriptorius and 2.0 -2.4 mm deep from the dorsal medullary surface. The sites eliciting bradycardia in the nAmb were identified by microinjections of L-GLU (5 mM). The volume of all microinjections into the nAmb was 30 nl; the selection of this volume was based on our preliminary studies in which 30-nl volume of L-GLU (5 mM) elicited maximum bradycardic responses. The volumes were pressure ejected (30 -35 psi) and visually confirmed by the displacement of fluid meniscus in the barrel containing the solution. The duration of microinjection was 5-10 s. Microinjections (30 nl) of aCSF (pH 7.4) were used as controls.
Decerebration. Midcollicular decerebration was performed in isoflurane-anesthetized rats as described elsewhere (7). After the decerebration, isoflurane administration was discontinued and a stabilization period of 60 min was allowed.
Histology. At the end of the experiment, the sites of microinjections into the nAmb were marked by diluted India ink and the brain tissue was processed for histology as described elsewhere (7).
Drugs and chemicals. The following drugs and chemicals were used: Statistical analyses. The mean and SE were calculated for the maximum decreases in HR in response to microinjections of UCN1 or L-GLU into the nAmb. In the concentration-response studies, comparisons of the maximum decreases in HR in different groups of rats were made by using a one-way analysis of variance (ANOVA) followed by Tukey-Kramer's multiple comparison. In experiments testing for tachyphylaxis and effect of CRFR antagonists, comparisons of the maximum decreases in HR elicited by microinjection of UCN1 into the nAmb were made by using repeated-measures ANOVA followed by Tukey-Kramer's multiple comparison. Student's paired t-test was used for comparisons of maximum decreases in HR elicited by the following: 1) microinjection of UCN1 into the nAmb before and after the bilateral vagotomy and 2) microinjection of L-GLU into the nAmb before and after the microinjections of CRFR antagonist. Unpaired t-test was used for comparisons of the maximum decreases in HR elicited by microinjection of UCN1 into the nAmb in anesthetized and decerebrate rats. In all cases, the differences were considered significant at P Ͻ 0.05.
RESULTS
Baseline values for MAP and HR in urethane-anesthetized rats were 100.0 Ϯ 8.3 mmHg and 404 Ϯ 11.4 beats/min, respectively (n ϭ 45). The values for baseline MAP and HR in the decerebrate rats (n ϭ 5) were 92.1 Ϯ 2 mmHg and 411 Ϯ 34 beats/min, respectively. There were no significant differences (P Ͼ 0.05) between the baseline values of MAP and HR in urethane-anesthetized and decerebrate rats.
Concentration response of UCN1. Bradycardic responses without significant changes in MAP elicited by microinjections (30 nl each) of different concentrations of UCN1 into the nAmb are shown in Table 1 . The nAmb was previously identified by microinjections of L-GLU (5 mM), which elicited a decrease in HR (80 Ϯ 7.3 beats/min) without significant changes in MAP (n ϭ 10). Maximum bradycardic responses were elicited by the 0.25 mM concentration of UCN1. This concentration was selected for further studies in other experiments.
Reproducibility of UCN1 responses. The concentration of UCN1 that elicited maximal bradycardic responses (0.25 mM) was microinjected into the nAmb at least three times, at 40-min intervals (n ϭ 5). The decreases in HR induced by three consecutive microinjections of UCN1 were 38 Ϯ 5, 45.7 Ϯ 3, and 46 Ϯ 5 beasts/min, respectively (P Ͼ 0.05). Thus no tachyphylaxis of bradycardic responses was observed with repeated microinjections of UCN1 when the interval between injections was 40 min.
Site specificity of UCN1 responses. The concentrations of UCN1 (0.25 mM, 30 nl) that elicited maximal bradycardic responses when microinjected into the nAmb (n ϭ 5) did not elicit a response when injected intravenously. Microinjections of UCN1 (0.25 mM) into areas adjacent to the nAmb (e.g., ventral region of the dorsal medullary reticular nucleus; 0.6 mm rostral and 2.3 mm lateral to the calamus scriptorius and 2.6 mm deep from the dorsal medullary surface) elicited no HR responses.
Effect of UCN1 in decerebrate rats. The nAmb was identified by microinjection of L-GLU (5 mM) in a group of decerebrate rats (n ϭ 5); a decrease in HR (137 Ϯ 23 beats/min) was observed. Five minutes later, microinjections of UCN1 (0.25 mM) at the same site elicited bradycardia (49 Ϯ 2 beats/min), which was not statistically different (P Ͼ 0.05) when compared with bradycardia elicited by the microinjection of the same dose of UCN1 into the nAmb of urethane-anesthetized rats (45.7 Ϯ 2.7 beats/min).
Effect of bilateral vagotomy. The nAmb was identified by microinjection of L-GLU (5 mM); a decrease in HR (66.7 Ϯ 10.5 beats/min ) was observed. Five minutes later, microinjections of UCN1 (0.25 mM) at the same site elicited a bradycardia (42.8 Ϯ 2.1 beats/min). Forty minutes later, bilateral vagotomy was performed, and a 10-min period of stabilization was allowed. At this time, microinjection of UCN1 into the nAmb failed to elicit a bradycardic response (Table 2) . Five minutes later, L-GLU was microinjected into the nAmb; the bradycardic response to L-GLU was also abolished.
Effect of selective CRF1R antagonist on UCN1 responses. Microinjections of L-GLU (5 mM) into the nAmb elicited decreases in HR (80 Ϯ 13 beats/min) without concomitant changes in MAP (n ϭ 5). Five minutes later, microinjection of the UCN1 (0.25 mM) into the nAmb elicited a decrease in HR without significant changes in MAP ( Table 2) . Forty minutes later, microinjections of NBI 27914 (1 mM) did not attenuate the bradycardic responses to microinjections of UCN1 (0.25 mM) ( Table 2 ). In another group of rats (n ϭ 5), a higher concentration of CRF1R antagonist (1.5 mM) was microinjected into nAmb, which was followed by another microinjection of UCN1 (0.25 mM). The bradycardic responses to microinjections UCN1 (0.25 mM) were significantly attenuated ( Table 2 ). Within 40 -50 min, the bradycardic responses to microinjection of UCN1 into the nAmb (31.1 Ϯ 3.2 beats/min) recovered. A tracing of these results is shown in Fig. 1 .
Effect of iGLUR antagonists on UCN1-induced response. The nAmb was identified by microinjections of L-GLU (5 mM) as in other experiments (n ϭ 5). After an interval of 5 min, microinjections of UCN1 (0.25 mM) at the same site elicited bradycardia with no significant changes in MAP. Forty minutes later, NBQX (2 mM) and D-AP7 (5 mM) were microinjected sequentially (within 2 min) at the same site. The concentrations of NBQX and D-AP7 were selected from our previous report (24) . The microinjection of UCN1 (0.25 mM) was repeated at the same site within 8 -10 min. UCN1-induced decrease in HR was significantly attenuated by ionotropic glutamate receptor (iGLUR) antagonists ( Table 2) .
Effect of CRF1R antagonist on baroreflex. The nAmb was identified bilaterally by microinjections of L-GLU (5 mM); the decrease in HR was 80 Ϯ 7.3 beats/min (n ϭ 5). The following three protocols were used to test the baroreceptor function (Fig. 2) . First, control baroreflex responses were obtained before any microinjections into the nAmb; reflex decreases in HR (change from basal value) were 1.1 Ϯ 0.6, 2.6 Ϯ 1.2, 4.6 Ϯ 1.4, 6.6 Ϯ 1.7, 9.5 Ϯ 1.1, 13.4 Ϯ 1.9, and 17.4 Ϯ 2.2% in response to 10, 20, 30, 40, 50, 60, and 70 mmHg increases in MAP, respectively. Twenty minutes later, the same protocol was repeated after bilateral microinjections of aCSF into the nAmb; reflex decreases in HR Applicable values are means Ϯ SE. UCN1, urocortin1; nAmb, nucleus ambiguus; HR, heart rate; MAP, mean arterial pressure. The bradycardic response was significantly greater than the responses elicited by other concentrations; *P Ͻ 0.001. Values are means Ϯ SE. The antagonists and UCN1 were microinjected into the nAmb. *Abolition of the bradycardic response. †Decreases in HR before and after the antagonist were not significantly different (P Ͼ 0.05). ‡Decreases in HR after the antagonist were significantly smaller compared to the corresponding values before the antagonist (P Ͻ 0.05). NBQX, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo-(f)quinoxaline-7-sulfonamide disodium; D-AP7, D-(Ϫ)-2-amino-7-phosphono-heptanoic acid. were 1.1 Ϯ 0.5, 2.6 Ϯ 1.2, 4.1 Ϯ 1.4, 6.1 Ϯ 1.7, 9.4 Ϯ 1.5, 13.2 Ϯ 1.9, and 17.3 Ϯ 2.3%, respectively. After an interval of 20 min, the same protocol was repeated after bilateral microinjections of CRF1R antagonist (NBI 27914, 1.5 mM) into the nAmb; reflex decreases in HR were 1.1 Ϯ 0.3, 2.6 Ϯ 0.7, 3.9 Ϯ 0.7, 5.9 Ϯ 0.7, 9.3 Ϯ 0.8, 13.4 Ϯ 1.6, and 14.6 Ϯ 0.7%, respectively. No significant differences (P Ͼ 0.05) in the reflex HR decreases in response to different increases in MAP were observed after the microinjections of CRF1R antagonist into the nAmb. Microinjections of aCSF into the nAmb also did not alter reflex HR decreases. No significant changes in basal HR were elicited by bilateral microinjections of either the CRF1R antagonist or aCSF. The concentration of CRF1R antagonist (1.5 mM) used in these experiments was previously shown to completely block the effects of the maximally effective concentration of UCN1 (0.25 mM) in the nAmb.
Histology. The nAmb sites, where microinjections of L-GLU and UCN1 elicited bradycardia, were marked with India ink in 35 rats. Composite diagrams of the microinjection sites in the nAmb are presented in Fig. 3 .
DISCUSSION
The main observation in this study was that microinjections of UCN1 into the nAmb elicited bradycardic responses. There are no reports in the literature regarding the cardiovascular effects of UCN1 in the nAmb for comparison of our results. Local distortion of brain tissue or any nonspecific effects were not responsible for the bradycardic effects elicited by microinjections of UCN1 into the nAmb because microinjections of aCSF at the same site did not elicit any response. Concentrations of UCN1 microinjections (0.25 mM, 30 nl) into the nAmb that elicited maximum decreases in HR did not elicit a response when injected intravenously, indicating that leakage of UCN1, if any, from the microinjection site into the peripheral circu- lation was not responsible for the observed responses. The UCN1-induced bradycardic responses elicited from the nAmb were site specific because similar microinjections into the adjacent areas elicited no responses.
The mechanism of the bradycardic responses elicited by UCN1 microinjections into the nAmb can be explained as follows on the basis of our present knowledge regarding the medullary control of cardiac function (22, (35) (36) . UCN1 microinjections may have excited the neurons located in the region surrounding the compact formation of the nAmb, increasing the activity of vagal input to the heart and causing bradycardia. The bradycardic responses to microinjections of UCN1 into the nAmb were blocked by prior microinjections of NBI 27914 at the same site, suggesting that these responses were mediated via CRF1Rs in this brain area. NBI 27914 has been reported to be a selective antagonist for CRF1Rs (1) . Furthermore, this antagonist did not alter responses to microinjections of an unrelated agonist, L-GLU, into the nAmb. Because unilateral or bilateral microinjections of the antagonist alone into the nAmb area did not elicit significant changes in basal MAP and HR, it was concluded that under normal physiological conditions CRF1Rs in the nAmb were not under tonic control of endogenous UCN1.
The bradycardic effects elicited by microinjections of UCN1 into the nAmb were lesser in magnitude than those elicited by microinjections of L-GLU. Weaker responses to UCN1 may be due to lesser density of CRFRs in the nAmb (8, 38) .
Microinjections of UCN1 into the nAmb showed a bellshaped concentration response. A similar type of concentration response has been reported for microinjections of urocortins into the mNTS (25) . This type of concentration response has been explained by homotropic allostery in which the agonist at higher concentrations binds to a modulator site, which is different from the primary binding site, and thereby affects the function of the receptor, resulting in attenuated responses (3) . Another possibility is that, at higher concentrations, UCN1 may activate inhibitory pathways located in the nAmb. For example, the presence of inhibitory glycinergic and GABAergic pathways has been reported in the nAmb (13) . Activation of these pathways by UCN1 at higher concentrations is expected to reduce the vagal input to the heart and increase HR, causing a reduction in UCN1-induced bradycardic responses. The role of inhibitory mechanisms in the nAmb in reducing the cardiac responses at higher concentrations of UCN1 remains to be tested.
In midcollicular decerebrate rats, microinjections of UCN1 into the nAmb elicited bradycardic responses, which were not statistically different from those elicited in urethane-anesthetized rats. These results suggested that urethane anesthesia did not alter the responses to UCN1 qualitatively or quantitatively. Moreover, the presence of neural structures located rostral to the brainstem (e.g., hypothalamus) was not necessary for UCN1-induced effects in the nAmb.
The decreases in HR induced by microinjections of UCN1 into the nAmb were partly mediated via iGLURs. This conclusion was based on our observation that microinjections of iGLUR antagonists into the nAmb attenuated the UCN1-induced decreases in HR. We have previously reported similar actions of urocortins in the mNTS in which the specificity of the iGLUR antagonists used was also established (24) . It may be pointed out that most neurons derive their on-going activity from glutamatergic synaptic inputs and that iGLUR antagonists may attenuate the effect of exogenously applied excitatory substances by virtue of the fact that the neurons in the brain area under investigation may be hyperpolarized. Therefore, results using iGLUR antagonists need to be interpreted with caution. However, we have previously demonstrated that the doses of NBQX and D-AP7 used in this study did not attenuate the effect of exogenously applied excitatory substances indiscriminately because the effects of an unrelated agonist, carbachol, remained unaltered (16, 24) . The presence of glutamatergic inputs to the cardiac vagal neurons in the nAmb region has been reported (43) . UCN1 microinjections may have activated CRFRs on the terminals of glutamatergic inputs in the nAmb and released glutamate, which, in turn, elicited decreases in HR. Consistent with this conclusion is the report that activation of CRFRs released glutamate in other brain areas (e.g., the ventral tegmental area) (42) .
As mentioned in the introduction, there is very little information available regarding the central cardiovascular actions of urocortins. We have published studies on the actions of UCN1 and UCN3 in the NTS (24 -25) . In the present manuscript, we have focused on the action of UCN1 in the nAmb because neurons and fibers immunoreactive for this peptide and CRF1Rs have been reported to be present in this brain area (4, 18, 19, 38, 40) . UCN2 and UCN3 were not included in the present article because there is no evidence for the presence of these peptides or CRF2Rs in the nAmb (4, 18, 19, 32, 38, 40) . In this context, it may be noted that UCN1 mediates its actions via both CRF1Rs and CRF2Rs, whereas UCN2 and UCN3 mediate their actions primarily via CRF2Rs (14) .
Several pharmacological studies have shown that urocortins are involved in the regulation of stress, anxiety states, food consumption, social behaviors, and drug self-administration (17, 28, (33) (34) . Pharmacological studies conducted in our and other laboratories indicate that urocortins may play a role in cardiovascular regulation also (9, 10, 24 -25, 29 -31, 40, 41, 44, 46) . The presence of UCN1-positive neurons, fibers, and CRF1Rs in the nAmb and adjacent areas (4, 38, 40) is of interest in the context of our results. It is possible that UCN1-containing neurons are activated in the nAmb in some pathological situations, releasing UCN1 in this nucleus and causing bradycardia. However, further studies are warranted to establish the cardiovascular and other functions of endogenous urocortins.
The blockade of CRF1Rs in the nAmb did not significantly alter baroreflex-induced bradycardia. This observation rules out the possibility that UCN1 may be a neurotransmitter released in the nAmb in response to baroreflex activation. In this context, it may be noted that published reports suggest that glutamate may be the neurotransmitter in the nAmb that is mediating reflex bradycardic responses (43) . The facts that microinjections of the CRF1R antagonist alone into the nAmb did not elicit significant HR responses and did not alter baroreflex-induced bradycardia indicate that UCN1 in the nAmb does not have a tonic influence on HR control under normal states. However, our results showed that activation of CRF1Rs by UCN1 elicits vagally mediated bradycardia. This observation prompts a speculation that UCN1 may be released in the nAmb during some pathological states (e.g., heart failure) to counterbalance disease-induced tachycardia.
The potential clinical significance of our results regarding centrally mediated bradycardic effect of UCN1 can be speculated to be as follows. There is a general consensus that, irrespective of the etiology, the first manifestation of congestive heart failure is usually tachycardia. Bradycardic responses elicited by UCN1 via its central action on the nAmb neurons could be beneficial in this situation. This possibility becomes relevant in view of the reports that peripherally administered urocortins can cross blood-brain barrier by a unique transport system (28) . However, it should be noted that positive chronotropic and inotropic effects exerted by the peripheral administration of UCN1 may have an adverse impact on myocardial oxygen demand and may offset the potential beneficial effects of this peptide in heart failure (29, 30) . The potential beneficial and adverse actions of UCN1 remain to be carefully assessed.
In summary, microinjections of UCN1 into the nAmb elicited bradycardic responses, which were mediated via CRF1Rs. iGLURs in the nAmb also participated in the UCN1-induced bradycardia. It was concluded that activation of neurons in the nAmb region caused bradycardia via increase in vagal activity because bilateral vagotomy abolished the bradycardic effect of UCN1.
GRANTS

